GlassScriptPhysician profile
Eugene Brannon Morris
NPI 1124024849
$3,420.67
in general payments reported to CMS, 2019-2025
46 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $164 · 2021: $591 · 2022: $432 · 2023: $544 · 2024: $476 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Education: $20.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.41 |
| Education | $20.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $387.90 | 2021 | |
| Ucb, INC. | $383.01 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Sunovion Pharmaceuticals INC. | $197.91 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $192.75 | 2019-2024 | Ultomiris, Soliris |
| Abbvie INC. | $191.94 | 2022-2025 | |
| Greenwich Biosciences, INC. | $186.78 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $173.80 | 2023-2025 | Daybue, Nuplazid |
| Teva Pharmaceuticals USA, INC. | $129.71 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Catalyst Pharmaceuticals, INC. | $103.01 | 2023-2025 | Firdapse |
| Allergan, INC. | $85.64 | 2019-2022 | |
| Argenx US, INC. | $85.43 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $81.20 | 2021-2024 | Rexulti |
| Biogen, INC. | $80.29 | 2022-2025 | Vumerity, Spinraza, Plegridy |
| Eisai INC. | $79.86 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $78.34 | 2023-2025 | Dysport |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.